Company Encyclopedia
View More
name
ArrowHead Pharma
ARWR.US
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy.
1.946 T
ARWR.USMarket value -Rank by Market Cap -/-

Financial Score

04/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking63/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE-0.50%D
    • Profit Margin-0.20%D
    • Gross Margin100.00%A
  • Growth ScoreA
    • Revenue YoY23258.15%A
    • Net Profit YoY99.73%A
    • Total Assets YoY21.54%A
    • Net Assets YoY163.48%A
  • Cash ScoreC
    • Cash Flow Margin-50855.18%E
    • OCF YoY23258.15%A
  • Operating ScoreB
    • Turnover0.66B
  • Debt ScoreD
    • Gearing Ratio63.66%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Arrowhead Pharmaceuticals (NASDAQ:ARWR) Hits New 52-Week High After Analyst Upgrade

    Arrowhead Pharmaceuticals (NASDAQ:ARWR) reached a new 52-week high after HC Wainwright raised its price target from $80 to $85, maintaining a buy rating. The stock traded as high as $59.27, closing at $58.53. Other analysts have also issued positive ratings, contributing to the stock's rise. Insiders sold shares recently, and institutional investors have been active in trading. Arrowhead Pharmaceuticals has a market cap of $7.93 billion and develops medicines for intractable diseases.

    Market Beat·
    US
    ARWR
    -0.64%
    Market Beat·
    US
    ARWR
    -0.64%

    Arrowhead Pharmaceuticals shares are trading higher. Yesterday, the company announced the FDA granted Breakthrough Therapy designation to investigational plozasiran as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia. Also, HC Wainwright raised its price target from $80 to $85 on the stock.

    benzinga_article·
    US
    ARWR
    -0.64%
    benzinga_article·
    US
    ARWR
    -0.64%

    Creative Planning Buys 19,194 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

    Creative Planning increased its stake in Arrowhead Pharmaceuticals by 72.5% in Q2, owning 45,662 shares valued at $721,000. Other hedge funds also adjusted their positions. Insiders sold 43,750 shares worth $1.64 million. Analysts have mixed ratings, with a consensus of 'Moderate Buy' and a target price of $53.33. Arrowhead's stock opened at $57.95, with a market cap of $7.87 billion.

    Market Beat·
    US
    ARWR
    -0.64%
    Market Beat·
    US
    ARWR
    -0.64%

    Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation For Plozasiran

    Arrowhead Pharmaceuticals Inc :ARROWHEAD PHARMACEUTICALS RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR PLOZASIRAN IN SEVERE HYPERTRIGLYCERIDEMIAARROWHEAD PHARMACEUTICALS - TO COMPLETE PHASE 3 STUDIES BY MID-2026ARROWHEAD PHARMACEUTICALS: INTENDS TO SUBMIT A SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) TO FDA BY YEAR-END 2026

    Reuters·
    US
    ARWR
    -0.64%
    Reuters·
    US
    ARWR
    -0.64%

    Arrowhead Pharmaceuticals Director Mauro Ferrari Reports Sale of Common Shares

    Mauro Ferrari, Director at Arrowhead Pharmaceuticals Inc., reported the sale of common shares of the company. This information was published via EDGAR by Arrowhead Pharmaceuticals on December 01, 2025. The news is generated by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    ARWR
    -0.64%
    Reuters·
    US
    ARWR
    -0.64%
    © 2025 Longbridge｜Disclaimer